InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
7
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-52.9%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by PELLETIER SAUNDRA L, Chairman & CEO. Insider active across 3 companies, notably Evofem Biosciences, Inc.. Aggregated, 13 disclosures have been published. Breakdown: 7 buys · 0 sell. Total volume traded: €263k. History available since 20 May 2021. The latest transaction was disclosed on 31 December 2022 (Disposition). Regulator: SEC (Form 4). The full history is free.
Declarations13 total
50,000 shares0Common StockSEC:0001251371-23-000002:0
141,000 shares@ US$0.35255.38% mcap15.7% of flowCommon StockSEC:0001618835-22-000130:0
Ideal exit: 21 Feb 2023 (T+270)
750,000 shares0Common StockSEC:0001618835-22-000028:0
300,000 shares0Common StockSEC:0001618835-22-000004
300,000 shares0Common StockSEC:0001618835-22-000004:0
135,000 shares@ US$0.37515.3% of flowCommon StockSEC:0001618835-21-000271
Ideal exit: 16 Sept 2022 (T+270)
135,000 shares@ US$0.3755.23% mcap15.3% of flowCommon StockSEC:0001618835-21-000271:0
Ideal exit: 16 Sept 2022 (T+270)
6,545 shares@ US$3.8250.0% of flowCommon StockSEC:0001209191-21-048272
Ideal exit: 22 Apr 2022 (T+270)
6,545 shares@ US$3.8250.0% of flowCommon StockSEC:0001209191-21-048272:0
Ideal exit: 22 Apr 2022 (T+270)
50,000 shares@ US$1.034.91% mcap14.3% of flowCommon StockSEC:0001618835-21-000147:0
Ideal exit: 7 Mar 2022 (T+270)
50,000 shares@ US$1.0314.3% of flowCommon StockSEC:0001618835-21-000147
Ideal exit: 7 Mar 2022 (T+270)
105,300 shares@ US$0.86100.0% of flowCommon StockSEC:0001618835-21-000133
105,300 shares@ US$0.868.60% mcap25.1% of flowCommon StockSEC:0001618835-21-000133:0
13 of 13 declarations
About PELLETIER SAUNDRA L
Saundra L. Pelletier is the Chairman & CEO of Evofem Biosciences, Inc. and Tracon Pharmaceuticals, Inc. She also serves as a Director at these companies. Her responsibilities include strategic and operational leadership, aiming to maximize shareholder value and ensure sustainable growth.
